TCR² Therapeutics
Financing Rounds
- Public
- Exit
Round Led by Symbiosis
Round Led by Symbiosis
TCR² Therapeutics is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA).
View Website
Modality
- Cell Therapy
Indication
- Oncology
Development Status
- Phase 2